Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib, Lisaftoclax, and Rituximab in R/R DLBCL
NCT07255963Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Nov 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirtobrutinib, lisaftoclax in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Soochow University. Started Nov 2025; status: recruiting.
02
Drugs
pirtobrutiniblisaftoclax
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07255963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07255963.